Methods for inhibiting the activity of the P40 subunit of human IL-12

US7883704B2 · kind B2 · utility

Assignee

• Abbott GmbH & Co. KG · DE

Inventors

• Jochen G. Salfeld · North Grafton, US
• Michael Roguska · Cambridge, US
• Michael Paskind · Sterling, US
• Subhashis Banerjee · Hamden, US
• Daniel Edward Tracey · Harvard, US
• Michael White · Framingham, US
• Zehra Kaymakcalan · Westborough, US
• Boris Labkovsky · Framingham, US
• Paul Sakorafas · Newton, US
• Geertruida M. Veldman · Sudbury, US
• Amy Venturini · Lexington, US
• Angela Widom · Acton, US
• Stuart Friedrich · Cary, US
• Nicholas W. Warne · Andover, US
• Angela Kantor · Pepperell, US
• John Gawain Elvin · Royston, GB
• Alexander Robert Duncan · Buckley, GB
• Elaine Joy Derbyshire · Royston, GB
• Sara Carmen · Cambridge, GB
• Stephen J. Smith · Los Gatos, US
• Thor Las Holtet · Rua W Três, DK
• Sarah Leila Du Fou · Hertford, GB

Key dates

• Filing date: Dec 22, 2006
• Grant date: Feb 8, 2011
• Expiry date: Jan 29, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.